Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Jan 07, 2024
Unmatched Trading Prowess: Tickeron's Top Robot Dominates with Over 70% Profitable Trades Amid Market Uncertainty!

Unmatched Trading Prowess: Tickeron's Top Robot Dominates with Over 70% Profitable Trades Amid Market Uncertainty!

Tickeron's quant team is thrilled to introduce the standout performer of the week, particularly noteworthy given the recent downturn in major stock indices. Despite the challenging market conditions, our quant team takes pride in highlighting the robot's exceptional achievement—delivering over 70% profitable signals for both long and short positions. This remarkable success can be attributed to its distinctive strategy, meticulously crafted to evaluate short-term trends in high-volatility stocks.

Swing Trader Pro: The Most Active Stocks with High Volatility (TA)

Click to view full description and closed trades for free!

 

Unleashing Precision Trading with Tickeron's AI Robot

Embark on a journey into the dynamic world of high-volatility stocks with our specially crafted AI Robot. Meticulously designed by Tickeron's expert quant team, this sophisticated algorithm blends classical and proprietary indicators to create a powerhouse for traders seeking maximum profitability.

Harnessing Mathematical Mastery for Daily Analysis

Our robot's mathematical prowess comes to life each day, meticulously analyzing short-term trends for individual stocks. The integration of machine learning algorithms ensures optimized parameters for each stock, enhancing the precision of trade signals and maximizing profits.

Strategic Trading Initiatives

Experience the agility of our robot as it strategically initiates trades based on signal strength. Depending on the quality of the signal, the robot can open multiple trades simultaneously, ensuring optimal profit extraction from the market's most effective signals.

Advanced Risk Management

Navigate the market with confidence through our advanced risk management system. A fixed limit take-profit order and a dynamic trailing stop algorithm work in tandem to safeguard your investments. The robot adapts in real-time to price dynamics, placing stop market orders strategically for optimal risk mitigation.

Experience Precision Trading with Advanced Technology. Don't Miss the Opportunity for the Ultimate Trading Excellence.

Here are the latest trades:

Related Ticker: EDIT, AEHR, EVGO, NIO, TLRY

EDIT in +12.65% Uptrend, rising for three consecutive days on July 02, 2026

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where EDIT advanced for three days, in of 232 cases, the price rose further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 10 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

The Aroon Indicator entered an Uptrend today. In of 153 cases where EDIT Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for EDIT moved out of overbought territory on July 09, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 30 similar instances where the indicator moved out of overbought territory. In of the 30 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Momentum Indicator moved below the 0 level on July 14, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on EDIT as a result. In of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for EDIT turned negative on July 14, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at .

EDIT moved below its 50-day moving average on July 20, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for EDIT crossed bearishly below the 50-day moving average on July 24, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where EDIT declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

EDIT broke above its upper Bollinger Band on July 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. EDIT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (90.909) is normal, around the industry mean (19.560). P/E Ratio (0.000) is within average values for comparable stocks, (38.308). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.584). Dividend Yield (0.000) settles around the average of (0.020) among similar stocks. P/S Ratio (6.211) is also within normal values, averaging (419.666).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EDIT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Moderna (NASDAQ:MRNA), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Nektar Therapeutics (NASDAQ:NKTR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.07B. The market cap for tickers in the group ranges from 58 to 122.67B. VRTX holds the highest valuation in this group at 122.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -2%. For the same Industry, the average monthly price growth was -7%, and the average quarterly price growth was 2,132%. SPRC experienced the highest price growth at 88%, while VYNE experienced the biggest fall at -99%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 7%. For the same stocks of the Industry, the average monthly volume growth was -30% and the average quarterly volume growth was -52%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 81
Price Growth Rating: 58
SMR Rating: 94
Profit Risk Rating: 93
Seasonality Score: 4 (-100 ... +100)
View a ticker or compare two or three
EDIT
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

a company which translates genome editing technology into a novel class of human therapeutics

Industry Biotechnology

Profile
Details
Industry
Biotechnology
Address
11 Hurley Street
Phone
+1 617 401-9000
Employees
87
Web
https://www.editasmedicine.com
Interact to see
Advertisement
The Travelers Companies, Inc.(TRV), a major player in the property and casualty insurance market, reported fourth-quarter 2025 results on January 21, 2026, closing out a year marked by underwriting discipline despite volatile weather activity and pricing pressures. The results underscore Travelers’ ability to generate strong profitability while navigating challenges in personal insurance lines and heightened catastrophe risk.
FingerMotion, Inc. (NASDAQ: FNGR) reported fiscal third-quarter 2026 results on January 15, 2026, triggering a sharp selloff as investors reacted to a steep revenue decline and widening losses. Shares fell roughly 32% following the release after the mobile services provider disclosed a 32% year-over-year drop in revenue and a net loss of $1.67 million for the quarter ended November 30, 2025.
CSX (NASDAQ: CSX) reports Q4 2025 earnings after market close on January 22, 2026, with consensus EPS ~$0.42 and revenue ~$3.57 billion. Union Pacific (NYSE: UNP) follows on January 27, with EPS expected near $2.89 and revenue around $6.15 billion. Norfolk Southern (NYSE: NSC) closes the week on January 29, with consensus EPS ~$2.77.
The SPDR S&P Aerospace & Defense ETF (XAR) has surged to a new 52-week high above $281 this week, climbing 21% month-to-date and 20% year-to-date through January 2026. The rally, driven by robust sector momentum and a clean technical breakout, is outpacing broader indices like the S&P 500. XAR’s equal-weighted structure amplifies gains from top aerospace and defense holdings in missiles, aircraft, and space systems, attracting significant trader and institutional attention amid heightened geopolitical tensions.
The iShares U.S. Aerospace & Defense ETF (ITA) continues to attract trader attention, building on a remarkable 47.7% gain in 2025 amid rising defense budgets and heightened global security concerns. The ETF is approaching all-time highs, with top holdings such as GE Aerospace and RTX Corporation driving the rally. Traders are adding positions on dips while monitoring confirmation above key resistance levels near recent peaks, anticipating a potential technical breakout.
Chevron’s upcoming Q4 report highlights its first full quarters integrating Hess, following record Q3 production of 4.1 million barrels of oil equivalent per day (MMboe/d). Comparing CVX with ExxonMobil and Shell provides insight into how each supermajor is navigating a volatile oil market with prices hovering below $60 per barrel.
SoFi Technologies is set to report Q4 and full-year 2025 earnings on January 30, 2026, closing out a pivotal year for the digital finance platform. With its fiscal year ending December 31, the report follows a strong Q3 that featured record net revenue of $962 million and member growth to 12.6 million, a 35% year-over-year increase.
ASML reported Q4 2025 net sales of $9.7 billion, gross margin of 52.2%, net income of $2.8 billion, and record net bookings of $13.2 billion, including $7.4 billion in EUV orders.
IDEXX Laboratories (IDXX) reports Q4 2025 earnings on February 2, 2026, with analysts expecting continued strength in recurring revenue from companion animal diagnostics. Danaher (DHR) reports on January 28, while Thermo Fisher Scientific (TMO) follows in early February, with both facing low-single-digit core growth expectations across life sciences and diagnostics.
NIO Inc. (NIO) produced its one-millionth vehicle this week at its Hefei facility, closing out a record 2025 delivery total of 326,028 units, up 46.9% year over year. The milestone, announced January 6, reflects accelerating demand for core models such as the ES8 SUV and newer brands ONVO and Firefly.
Faraday Future Intelligent Electric Inc. (FFAI) shares traded near $1.02 this week following announcements of a non-binding $10 million stock purchase term sheet with AIxCrypto (AIxC) and preparations for a Stockholders’ Day on January 7, 2026. Trading volume spiked amid broader EV volatility, highlighting investor attention on FFAI’s pivot toward AI-enhanced mobility and robotics.
BTQ Technologies Corp. (BTQ), formerly BTQQF, launched the Bitcoin Quantum testnet this week—the first quantum-safe Bitcoin fork, 17 years after Bitcoin’s genesis block. The move coincided with inclusion in the $524.5 million VanEck Quantum Computing UCITS ETF, boosting European investor visibility.
VEU targets large- and mid-cap ex-U.S. stocks with ~3,800 holdings. VXUS offers broad all-cap exposure, including ~8,600 stocks across small-, mid-, and large-cap companies.
Apple (AAPL) reports Q1 FY2026 earnings on January 29, with consensus revenue at $138.5B and EPS at $2.67, supported by strong demand for iPhone 17 models, higher average selling prices, and continued Services growth. Microsoft (MSFT) reports Q2 FY2026 on January 28, expecting $80.3B revenue and $3.91 EPS, driven by Azure AI adoption and enterprise cloud expansion, though elevated capex spending (~$35B/quarter) remains under scrutiny.
Visa Inc. (V), the global payments network leader, reports Q1 FY2026 earnings on January 29, 2026, for the period ending December 31, 2025. This marks the start of FY2026 following a strong FY2025, where net revenue reached $40 billion (+11%) and EPS climbed to $11.47 (+14%). Investors are watching closely for insights into consumer spending, cross-border travel recovery, and digital payment adoption.
Novartis (NVS) reports Q4/FY 2025 earnings on February 4, 2026, with consensus calling for ~$1.99 EPS on ~$13.7 billion in revenue. Sanofi (SNY) delivered strong FY 2025 results on January 29, reporting €43.6 billion in sales (+9.9% CER) and 15% business EPS growth.
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
MUFG is expected to report Q3 FY2026 EPS of about $0.30, broadly in line with its recent pattern of earnings beats.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Unmatched Trading Prowess: Tickeron's Top Robot Dominates with Over 70% Profitable Trades Amid Market Uncertainty!